October 2024 in “Stem Cell Research & Therapy” CGF therapy may effectively treat psoriasis by reducing inflammation.
April 2024 in “JEADV clinical practice” Upadacitinib significantly improved both rheumatoid arthritis and alopecia areata in a patient.
October 2024 in “Dermatologica Sinica” Recognizing unusual symptoms in Crohn's disease is crucial for proper treatment.
March 2025 in “Future Oncology” Sacituzumab govitecan improves quality of life and extends life for breast cancer patients compared to standard chemotherapy.
May 2025 in “The Journal of Rheumatology” Anti-CD19 therapy may help treat SLE and NMOSD.
1 citations
,
November 2023 in “Journal of neurology” A patient with a nerve disorder died from infection complications after developing insulin resistance from a treatment.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
2 citations
,
October 2023 in “JDDG Journal der Deutschen Dermatologischen Gesellschaft” Dupilumab significantly improved a 5-year-old girl's prurigo nodularis without side effects.
10 citations
,
May 2020 in “Dermatologic therapy” Tildrakizumab significantly improved recalcitrant lichen planopilaris and frontal fibrosing alopecia.
March 2026 in “International Journal of Pharmaceutics and Drug Analysis” The polyherbal emulgel is a promising treatment for rheumatoid arthritis with effective and sustained results.
1 citations
,
March 2019 in “Journal of Interdisciplinary Medicine” A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.
June 2024 in “International Journal of Dermatology” Upadacitinib may effectively treat resistant lichen planopilaris.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
February 2025 in “Canadian Journal of Health Technologies” Baricitinib is effective and cost-efficient for treating severe alopecia areata in adults.
14 citations
,
January 2017 in “Dermatology Online Journal” Adalimumab can cause hair loss and scalp issues in some psoriasis patients.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.
1 citations
,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
1 citations
,
April 2025 in “Skin Health and Disease” Abrocitinib is being evaluated for safety and effectiveness in treating moderate to severe atopic dermatitis.
Dupilumab helped improve skin and prevent new lesions in a child with a rare immune disorder and severe eczema.
2 citations
,
May 2020 in “JAAD case reports” Ruxolitinib can cause a delayed skin reaction on the nose.
4 citations
,
October 2023 in “Journal of Medicine and Life” UDCA reduces inflammation and joint damage in rheumatoid arthritis.
2 citations
,
September 2023 in “Journal of the American Academy of Dermatology” Ixekizumab quickly and effectively clears palmoplantar psoriasis in both adults and children.
37 citations
,
October 2014 in “JAMA dermatology” A woman with severe hair loss was successfully treated with the drug adalimumab.
4 citations
,
January 2019 in “Einstein (São Paulo)” Dupilumab improved severe atopic dermatitis in a patient who didn't respond to other treatments.
November 2010 in “Value in Health” Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.
9 citations
,
January 2015 in “Dermatology Online Journal” A patient with Crohn's disease grew back their hair after stopping Adalimumab, which had caused hair loss.
5 citations
,
December 2023 in “Clinical Case Reports” Adalimumab effectively stabilized severe folliculitis decalvans, preventing further hair loss and inflammation.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
Infliximab was effective in treating a scalp condition that did not respond to other treatments.